In addition, clinical studies of checkpoint inhibitors, such as anti-CTLA4 antibodies and anti-program death (PD)-1 antibodies, will be needed to improve the disease control in patients with LMD in the future. The gene discussed is CTLA4; the disease is Langer mesomelic dysplasia.